ALSUntangled #67: rituximab.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(5-6): 544-547, 2023 08.
Article
en En
| MEDLINE
| ID: mdl-36106861
ABSTRACT
ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Rituximab
/
Esclerosis Amiotrófica Lateral
Límite:
Humans
Idioma:
En
Revista:
Amyotroph Lateral Scler Frontotemporal Degener
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos